OSLO, Norway, May 31, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster describinga preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin's lymphoma (NHL) cell lines to BetalutinŽ (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Stockholm,
The abstract is available online (click here) and the poster will be available on the company's website at: www.nordicnanovector.com following the presentation on 15 June.
Poster details Abstract PF642 Abstract title: Systems biology analysis of responsiveness of non-Hodgkin lymphoma B-cell lines to CD37 targeting radioimmunotherapy Authors: Melhus, KB et al. Date: Friday 15 June Time: 17:30-19:00 (CEST)
For further information, please contact: Malene Brondberg, VPInvestor Relations and Corporate Communications Tel/Cell: + 44-7561-431-762 Email: firstname.lastname@example.org
Media enquiries: Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: email@example.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is BetalutinŽ, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of BetalutinŽ in core markets. Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-pre-clinical-study-of-betalutin-effect-on-nhl-cells-at-european-hematology-association-meeting-300657228.html
SOURCE Nordic Nanovector
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All